Wechselwirkungen von Beclometason

Beclometason (Qvar, Beconase), ein Kortikosteroid, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 339 dokumentierte Wechselwirkungen: 29 schwerwiegende, 219 mittelschwere, 91 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (29)

  • AbirateronCYP2D6-HemmerSchwerwiegend

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (Fachinformation zu Abirateron, Warnhinweise und Vorsichtsmaßnahmen)

  • AdalimumabImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

  • AdrenalinSympathomimetikumSchwerwiegend

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

  • ArformoterolBeta-Adrenozeptor-AgonistSchwerwiegend

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (Fachinformation zu Arformoterol, Gegenanzeigen)

  • ArsentrioxidQT-verlängerndes ArzneimittelSchwerwiegend

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (Fachinformation zu Arsentrioxid, Boxed Warning (umrahmter Warnhinweis))

  • Atazanavirantiretrovirales ArzneimittelSchwerwiegend

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

  • AxitinibSchwerwiegend

    Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (Fachinformation zu Axitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BaricitinibJAK-InhibitorSchwerwiegend

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Baricitinib, Boxed Warning (umrahmter Warnhinweis))

  • DocetaxelSchwerwiegend

    Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

  • Emtricitabin, Rilpivirin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Gegenanzeigen)

  • EtanerceptImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Etanercept, Boxed Warning (umrahmter Warnhinweis))

  • FormoterolBeta-Adrenozeptor-AgonistSchwerwiegend

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (Fachinformation zu Formoterol, Gegenanzeigen)

  • Fosamprenavirantiretrovirales ArzneimittelSchwerwiegend

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (Fachinformation zu Fosamprenavir, Arzneimittelwechselwirkungen)

  • InfliximabImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Infliximab, Boxed Warning (umrahmter Warnhinweis))

  • KetoconazolAzol-AntimykotikumSchwerwiegend

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

  • LovastatinStatinSchwerwiegend

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (Fachinformation zu Lovastatin, Gegenanzeigen)

  • MifepristonCYP3A4-HemmerSchwerwiegend

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (Fachinformation zu Mifepriston, Boxed Warning (umrahmter Warnhinweis))

  • MitotanCYP3A4-InduktorSchwerwiegend

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (Fachinformation zu Mitotan, Boxed Warning (umrahmter Warnhinweis))

  • MoexiprilACE-HemmerSchwerwiegend

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (Fachinformation zu Moexipril, Warnhinweise)

  • Rilpivirinantiretrovirales ArzneimittelSchwerwiegend

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (Fachinformation zu Rilpivirin, Gegenanzeigen)

  • SalmeterolBeta-Adrenozeptor-AgonistSchwerwiegend

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

  • SirolimusImmunsuppressivumSchwerwiegend

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (Fachinformation zu Sirolimus, Warnhinweise und Vorsichtsmaßnahmen)

  • SomatropinSchwerwiegend

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (Fachinformation zu Somatropin, Arzneimittelwechselwirkungen)

  • TocilizumabImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Tocilizumab, Boxed Warning (umrahmter Warnhinweis))

  • TofacitinibImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Tofacitinib, Boxed Warning (umrahmter Warnhinweis))

  • TrandolaprilACE-HemmerSchwerwiegend

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (Fachinformation zu Trandolapril, Warnhinweise)

  • TretinoinRetinoidSchwerwiegend

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Fachinformation zu Tretinoin, Boxed Warning (umrahmter Warnhinweis))

  • Umeclidiniumbromid und VilanterolAnticholinergikumSchwerwiegend

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (Fachinformation zu Umeclidiniumbromid und Vilanterol, Gegenanzeigen)

  • UpadacitinibImmunsuppressivumSchwerwiegend

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Upadacitinib, Boxed Warning (umrahmter Warnhinweis))

Mittelschwere Wechselwirkungen (219)

  • AcetylsalicylsäureNSARMittelschwer

    The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (Fachinformation zu Acetylsalicylsäure, Warnhinweise)

  • AclidiniumbromidAnticholinergikumMittelschwer

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Fachinformation zu Aclidiniumbromid, Arzneimittelwechselwirkungen)

  • AfatinibMittelschwer

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Fachinformation zu Afatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • AlbendazolMittelschwer

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (Fachinformation zu Albendazol, Warnhinweise und Vorsichtsmaßnahmen)

  • AlemtuzumabImmunsuppressivumMittelschwer

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (Fachinformation zu Alemtuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • AlendronsäureBisphosphonatMittelschwer

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Fachinformation zu Alendronsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • AliskirenAntihypertensivumMittelschwer

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (Fachinformation zu Aliskiren, Warnhinweise und Vorsichtsmaßnahmen)

  • Alogliptin und MetforminDPP-4-HemmerMittelschwer

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

  • AlpelisibMittelschwer

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (Fachinformation zu Alpelisib, Warnhinweise und Vorsichtsmaßnahmen)

  • Amphotericin BAntimykotikumMittelschwer

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (Fachinformation zu Amphotericin B, Arzneimittelwechselwirkungen)

  • Azelastin und FluticasonAntihistaminikumMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Belladonna und OpiumOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Belladonna und Opium, Warnhinweise und Vorsichtsmaßnahmen)

  • BendamustinMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BenralizumabMittelschwer

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (Fachinformation zu Benralizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Bictegravir, Emtricitabin und Tenofoviralafenamidantiretrovirales ArzneimittelMittelschwer

    Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

  • BrivaracetamAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • BuprenorphinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Buprenorphin, Warnhinweise und Vorsichtsmaßnahmen)

  • Buprenorphin und NaloxonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Buprenorphin und Naloxon, Warnhinweise und Vorsichtsmaßnahmen)

  • BupropionAntidepressivumMittelschwer

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (Fachinformation zu Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

  • In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. (Fachinformation zu Butalbital, Acetylsalicylsäure und Koffein, Arzneimittelwechselwirkungen)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Warnhinweise und Vorsichtsmaßnahmen)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Warnhinweise und Vorsichtsmaßnahmen)

  • ButorphanolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Butorphanol, Warnhinweise)

  • Cannabidiol (verschreibungspflichtig)AntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbamazepinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CefoxitinCephalosporinMittelschwer

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (Fachinformation zu Cefoxitin, Warnhinweise und Vorsichtsmaßnahmen)

  • CelecoxibNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Celecoxib, Warnhinweise und Vorsichtsmaßnahmen)

  • CenobamatAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclosporinImmunsuppressivumMittelschwer

    …in perfusion > decrease in tubular function Increased uptake of Indium 111 labeled platelets or Tc-99m in colloid Therapy Responds to decreased cyclosporine Responds to increased steroids or antilymphocyte globulin A form of a cyclosporine-associated nephropathy is characterized by serial deterioration in renal function and morphologic changes in the kidneys. (Fachinformation zu Ciclosporin, Warnhinweise)

  • CiprofloxacinFluorchinolonMittelschwer

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Ciprofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

  • CladribinAntimetabolitMittelschwer

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (Fachinformation zu Cladribin, Arzneimittelwechselwirkungen)

  • ClobazamBenzodiazepinMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • ClonazepamBenzodiazepinMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CodeinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Codein, Warnhinweise und Vorsichtsmaßnahmen)

  • CytarabinAntimetabolitMittelschwer

    These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (Fachinformation zu Cytarabin, Warnhinweise)

  • DaptomycinAntibiotikumMittelschwer

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (Fachinformation zu Daptomycin, Warnhinweise und Vorsichtsmaßnahmen)

  • Darunavirantiretrovirales ArzneimittelMittelschwer

    Alternative corticosteroids including beclomethasone, prednisone, and prednisolone (for which PK and/or PD are less affected by strong CYP3A inhibitors relative to other steroids) should be considered, particularly for long term use. (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelMittelschwer

    Alternative corticosteroids including beclomethasone, prednisone and prednisolone (for which PK and/or PD are less affected by strong CYP3A inhibitors relative to other steroids) should be considered, particularly for long-term use. (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatMittelschwer

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Fachinformation zu Deferasirox, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • DenosumabMittelschwer

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Fachinformation zu Denosumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (Fachinformation zu Desogestrel und Ethinylestradiol, Vorsichtsmaßnahmen)

  • DesonidKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • DiclofenacNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac, Warnhinweise und Vorsichtsmaßnahmen)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac und Misoprostol, Warnhinweise und Vorsichtsmaßnahmen)

  • DicycloverinAnticholinergikumMittelschwer

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

  • DiflunisalNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Diflunisal, Warnhinweise)

  • DigoxinDigitalisglykosidMittelschwer

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (Fachinformation zu Digoxin, Warnhinweise und Vorsichtsmaßnahmen)

  • DupilumabMittelschwer

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (Fachinformation zu Dupilumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (Fachinformation zu Elexacaftor, Tezacaftor und Ivacaftor, Warnhinweise und Vorsichtsmaßnahmen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

  • ErlotinibMittelschwer

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EslicarbazepinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • EstradiolEstrogenMittelschwer

    Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Estradiol, Vorsichtsmaßnahmen)

  • Estradiol und Dienogestorales KontrazeptivumMittelschwer

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (Fachinformation zu Estradiol und Dienogest, Arzneimittelwechselwirkungen)

  • Estradiol und NorethisteronEstrogenMittelschwer

    Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Estradiol und Norethisteron, Warnhinweise und Vorsichtsmaßnahmen)

  • EthosuximidAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • EtodolacNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Etodolac, Warnhinweise)

  • Etravirinantiretrovirales ArzneimittelMittelschwer

    Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

  • Etynodioldiacetat und Ethinylestradiolorales KontrazeptivumMittelschwer

    The amount of both steroids should be considered in the choice of an oral contraceptive. (Fachinformation zu Etynodioldiacetat und Ethinylestradiol, Warnhinweise)

  • FelbamatAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FenoprofenNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Fenoprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • FentanylOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

  • FingolimodImmunsuppressivumMittelschwer

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (Fachinformation zu Fingolimod, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidMittelschwer

    Although QVAR REDIHALER may provide control of asthmatic symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid that is necessary for coping with these emergencies. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FlurbiprofenNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Flurbiprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FosphenytoinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • GabapentinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • GlimepiridSulfonylharnstoffMittelschwer

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

  • GlipizidSulfonylharnstoffMittelschwer

    …examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin,… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Fachinformation zu Glycerolphenylbutyrat, Arzneimittelwechselwirkungen)

  • HalobetasolKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • HaloperidolAntipsychotikumMittelschwer

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Fachinformation zu Haloperidol, Arzneimittelwechselwirkungen)

  • HydralazinVasodilatatorMittelschwer

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (Fachinformation zu Hydralazin, Warnhinweise)

  • HydrocodonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon, Warnhinweise und Vorsichtsmaßnahmen)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Chlorphenamin, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und HomatropinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Homatropin, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und IbuprofenOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Ibuprofen, Warnhinweise)

  • Hydrocodon und ParacetamolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydrocodon und Paracetamol, Warnhinweise)

  • HydrocortisonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • HydromorphonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Hydromorphon, Warnhinweise und Vorsichtsmaßnahmen)

  • IbandronsäureBisphosphonatMittelschwer

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (Fachinformation zu Ibandronsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • IbuprofenNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • Ibuprofen und FamotidinNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen und Famotidin, Warnhinweise und Vorsichtsmaßnahmen)

  • ImatinibCYP3A4-HemmerMittelschwer

    If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (Fachinformation zu Imatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • IndometacinNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Indometacin, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin aspartInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

  • Insulin degludecInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

  • Insulin detemirInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

  • Insulin glarginInsulinMittelschwer

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

  • Insulin lisproInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

  • IvacaftorCYP3A4-HemmerMittelschwer

    Although other risk factors were present in some cases (such as corticosteroid use and/or exposure to radiation), a possible risk attributable to KALYDECO cannot be excluded. (Fachinformation zu Ivacaftor, Warnhinweise und Vorsichtsmaßnahmen)

  • IvermectinMittelschwer

    Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (Fachinformation zu Ivermectin, Warnhinweise)

  • KetoprofenNSARMittelschwer

    PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Fachinformation zu Ketoprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • KetorolacNSARMittelschwer

    In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Ketorolac, Warnhinweise und Vorsichtsmaßnahmen)

  • KokainLokalanästhetikumMittelschwer

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

  • Konjugierte EstrogeneEstrogenMittelschwer

    Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (Fachinformation zu Konjugierte Estrogene, Vorsichtsmaßnahmen)

  • Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (Fachinformation zu Konjugierte Estrogene und Bazedoxifen, Warnhinweise und Vorsichtsmaßnahmen)

  • LacosamidAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • LamotriginAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Lenacapavirantiretrovirales ArzneimittelMittelschwer

    Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (Fachinformation zu Lenacapavir, Arzneimittelwechselwirkungen)

  • LevetiracetamAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • LevofloxacinFluorchinolonMittelschwer

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Levofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

  • Levonorgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (Fachinformation zu Levonorgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

  • LevorphanolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Levorphanol, Warnhinweise)

  • LevosalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Fachinformation zu Levosalbutamol, Warnhinweise und Vorsichtsmaßnahmen)

  • LevothyroxinSchilddrüsenhormonMittelschwer

    Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (Fachinformation zu Levothyroxin, Warnhinweise und Vorsichtsmaßnahmen)

  • Levothyroxin und LiothyroninSchilddrüsenhormonMittelschwer

    The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

  • LiothyroninSchilddrüsenhormonMittelschwer

    Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. (Fachinformation zu Liothyronin, Warnhinweise und Vorsichtsmaßnahmen)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (Fachinformation zu Lisinopril und Hydrochlorothiazid, Warnhinweise)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. * see Clinical Pharmacology ( 12.3 ) for magnitude of interaction. # refers to interaction with apalutamide. (Fachinformation zu Lopinavir und Ritonavir, Arzneimittelwechselwirkungen)

  • MargetuximabMittelschwer

    In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (Fachinformation zu Margetuximab, Warnhinweise und Vorsichtsmaßnahmen)

  • MedroxyprogesteronGestagenMittelschwer

    MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (Fachinformation zu Medroxyprogesteron, Warnhinweise und Vorsichtsmaßnahmen)

  • MefenaminsäureNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Mefenaminsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • MegestrolGestagenMittelschwer

    Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (Fachinformation zu Megestrol, Warnhinweise und Vorsichtsmaßnahmen)

  • MeloxicamNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Meloxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • MepolizumabMittelschwer

    Decrease corticosteroids gradually, if appropriate. (Fachinformation zu Mepolizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • MesuximidAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • MethadonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

  • MethazolamidCarboanhydrasehemmerMittelschwer

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (Fachinformation zu Methazolamid, Arzneimittelwechselwirkungen)

  • MethotrexatImmunsuppressivumMittelschwer

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (Fachinformation zu Methotrexat, Arzneimittelwechselwirkungen)

  • MethyldopaAntihypertensivumMittelschwer

    If not, corticosteroids may be given and other causes of anemia should be considered. (Fachinformation zu Methyldopa, Warnhinweise)

  • MethylprednisolonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • MethyltestosteronAndrogenMittelschwer

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

  • MetolazonThiaziddiuretikumMittelschwer

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (Fachinformation zu Metolazon, Arzneimittelwechselwirkungen)

  • MetyraponMittelschwer

    This can be corrected by giving appropriate doses of corticosteroids. (Fachinformation zu Metyrapon, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • MontelukastLeukotrienrezeptor-AntagonistMittelschwer

    Inhaled corticosteroid may be reduced gradually. (Fachinformation zu Montelukast, Warnhinweise und Vorsichtsmaßnahmen)

  • MorphinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Morphin, Warnhinweise und Vorsichtsmaßnahmen)

  • MoxifloxacinFluorchinolonMittelschwer

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Moxifloxacin, Warnhinweise und Vorsichtsmaßnahmen)

  • NabumetonNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Nabumeton, Warnhinweise)

  • NalbuphinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Nalbuphin, Warnhinweise)

  • Naltrexon und BupropionOpioidantagonistMittelschwer

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (Fachinformation zu Naltrexon und Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

  • NaproxenNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

  • Naproxen und EsomeprazolNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen und Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • NatalizumabImmunsuppressivumMittelschwer

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (Fachinformation zu Natalizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • NateglinidGlinidMittelschwer

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Fachinformation zu Natriumphenylacetat und Natriumbenzoat, Arzneimittelwechselwirkungen)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (Fachinformation zu Natriumphenylbutyrat, Arzneimittelwechselwirkungen)

  • NintedanibMittelschwer

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Nirmatrelvir und RitonavirVirostatikumMittelschwer

    Alternative corticosteroids including beclomethasone, prednisone, and prednisolone should be considered. (Fachinformation zu Nirmatrelvir und Ritonavir, Arzneimittelwechselwirkungen)

  • OcrelizumabImmunsuppressivumMittelschwer

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (Fachinformation zu Ocrelizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • OfloxacinFluorchinolonMittelschwer

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (Fachinformation zu Ofloxacin, Warnhinweise)

  • OliceridinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oliceridin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • OmalizumabMittelschwer

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Fachinformation zu Omalizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • OxaprozinNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Oxaprozin, Warnhinweise und Vorsichtsmaßnahmen)

  • OxcarbazepinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • OxycodonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxycodon, Warnhinweise und Vorsichtsmaßnahmen)

  • Oxycodon und ParacetamolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxycodon und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

  • OxymorphonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Oxymorphon, Warnhinweise und Vorsichtsmaßnahmen)

  • PamidronsäureBisphosphonatMittelschwer

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (Fachinformation zu Pamidronsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • Paracetamol und CodeinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Paracetamol und Codein, Warnhinweise)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • PasireotidMittelschwer

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (Fachinformation zu Pasireotid, Warnhinweise und Vorsichtsmaßnahmen)

  • PenicillaminMittelschwer

    Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Fachinformation zu Penicillamin, Warnhinweise)

  • Pentazocin und NaloxonOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Pentazocin und Naloxon, Warnhinweise)

  • PerampanelAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • PethidinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Pethidin, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenobarbitalBarbituratMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Phentermin und TopiramatZNS-StimulansMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Phenylephrinabschwellendes Mittel (Dekongestivum)Mittelschwer

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (Fachinformation zu Phenylephrin, Arzneimittelwechselwirkungen)

  • PhenytoinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

  • PiroxicamNSARMittelschwer

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

  • PonesimodImmunsuppressivumMittelschwer

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (Fachinformation zu Ponesimod, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidMittelschwer

    Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • PregabalinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • PrimidonAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und CodeinOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Promethazin und Codein, Warnhinweise und Vorsichtsmaßnahmen)

  • PropofolZNS-dämpfendes ArzneimittelMittelschwer

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (Fachinformation zu Propofol, Warnhinweise und Vorsichtsmaßnahmen)

  • RifampicinAntibiotikumMittelschwer

    …Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumMittelschwer

    …Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

  • RisedronsäureBisphosphonatMittelschwer

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (Fachinformation zu Risedronsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    …corticosteroids whose exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome and adrenal suppression.Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term… (Fachinformation zu Ritonavir, Arzneimittelwechselwirkungen)

  • Rocuroniumneuromuskulärer BlockerMittelschwer

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (Fachinformation zu Rocuronium, Warnhinweise und Vorsichtsmaßnahmen)

  • RufinamidAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • SalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Fachinformation zu Salbutamol, Warnhinweise und Vorsichtsmaßnahmen)

  • SalsalatNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Salsalat, Warnhinweise)

  • SulindacNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Sulindac, Warnhinweise)

  • Sumatriptan und NaproxenTriptanMittelschwer

    Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

  • Suxamethoniumneuromuskulärer BlockerMittelschwer

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Fachinformation zu Suxamethonium, Arzneimittelwechselwirkungen)

  • TapentadolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tapentadol, Warnhinweise und Vorsichtsmaßnahmen)

  • TemozolomidMittelschwer

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (Fachinformation zu Temozolomid, Warnhinweise und Vorsichtsmaßnahmen)

  • TemsirolimusMittelschwer

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Fachinformation zu Temsirolimus, Warnhinweise und Vorsichtsmaßnahmen)

  • TerbutalinBeta-Adrenozeptor-AgonistMittelschwer

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Fachinformation zu Terbutalin, Warnhinweise)

  • TeriparatidSchilddrüsenhormonMittelschwer

    Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (Fachinformation zu Teriparatid, Warnhinweise und Vorsichtsmaßnahmen)

  • TesamorelinMittelschwer

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Fachinformation zu Tesamorelin, Arzneimittelwechselwirkungen)

  • TestosteronAndrogenMittelschwer

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (Fachinformation zu Testosteron, Warnhinweise und Vorsichtsmaßnahmen)

  • TheophyllinMethylxanthinMittelschwer

    Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (Fachinformation zu Theophyllin, Warnhinweise)

  • TiagabinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • TiotropiumbromidAnticholinergikumMittelschwer

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Fachinformation zu Tiotropiumbromid, Arzneimittelwechselwirkungen)

  • TolmetinNSARMittelschwer

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Tolmetin, Warnhinweise)

  • TopiramatAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • TorasemidSchleifendiuretikumMittelschwer

    Corticosteroids and ACTH: Increased risk of hypokalemia. (Fachinformation zu Torasemid, Arzneimittelwechselwirkungen)

  • TramadolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tramadol, Warnhinweise und Vorsichtsmaßnahmen)

  • Tramadol und ParacetamolOpioidMittelschwer

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Fachinformation zu Tramadol und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

  • TrastuzumabMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidMittelschwer

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumMittelschwer

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (Fachinformation zu Triamteren und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • Valproat-Seminatrium (Divalproex)AntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • ValproinsäureAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • VigabatrinAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • VoriconazolAzol-AntimykotikumMittelschwer

    • Adrenal Dysfunction : Carefully monitor patients receiving voriconazole and corticosteroids (via all routes of administration) for adrenal dysfunction both during and after voriconazole treatment. (Fachinformation zu Voriconazol, Warnhinweise und Vorsichtsmaßnahmen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (Fachinformation zu Warfarin, Arzneimittelwechselwirkungen)

  • ZenocutuzumabMittelschwer

    Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (Fachinformation zu Zenocutuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ZoledronsäureBisphosphonatMittelschwer

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (Fachinformation zu Zoledronsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • ZonisamidAntiepileptikumMittelschwer

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (91)

  • AcarboseAntidiabetikumGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

  • AlteplaseGeringfügig

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Fachinformation zu Alteplase, Warnhinweise und Vorsichtsmaßnahmen)

  • AmfetaminZNS-StimulansGeringfügig

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Amfetamin, Arzneimittelwechselwirkungen)

  • Amfetamin und DexamfetaminZNS-StimulansGeringfügig

    Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Amfetamin und Dexamfetamin, Arzneimittelwechselwirkungen)

  • AmikacinAminoglykosidGeringfügig

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (Fachinformation zu Amikacin, Warnhinweise und Vorsichtsmaßnahmen)

  • AminophyllinMethylxanthinGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • AmiodaronAntiarrhythmikumGeringfügig

    Antithyroid drugs, β-adrenergic blockers, temporary corticosteroid therapy may be necessary to treat the symptoms of hyperthyroidism. (Fachinformation zu Amiodaron, Warnhinweise und Vorsichtsmaßnahmen)

  • AmpicillinPenicillin-AntibiotikumGeringfügig

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Fachinformation zu Ampicillin, Warnhinweise)

  • BempedoinsäureOATP1B1-HemmerGeringfügig

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (Fachinformation zu Bempedoinsäure, Warnhinweise und Vorsichtsmaßnahmen)

  • Benzylpenicillin (Penicillin G)Penicillin-AntibiotikumGeringfügig

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (Fachinformation zu Benzylpenicillin (Penicillin G), Warnhinweise)

  • BevacizumabGeringfügig

    Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Fachinformation zu Bevacizumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Bisoprolol und HydrochlorothiazidBetablockerGeringfügig

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Fachinformation zu Bisoprolol und Hydrochlorothiazid, Vorsichtsmaßnahmen)

  • BusulfanGeringfügig

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (Fachinformation zu Busulfan, Warnhinweise)

  • CalcitriolVitamin-D-AnalogonGeringfügig

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (Fachinformation zu Calcitriol, Arzneimittelwechselwirkungen)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Steroids or Adrenocorticotropic Hormone – Hypokalemia may develop during concomitant use of steroids or adrenocorticotropic hormone (ACTH). (Fachinformation zu Candesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • CefaclorCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefaclor, Warnhinweise)

  • CefadroxilCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefadroxil, Warnhinweise und Vorsichtsmaßnahmen)

  • CefdinirCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefdinir, Warnhinweise)

  • CefotetanCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefotetan, Warnhinweise)

  • CefprozilCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Cefprozil, Warnhinweise)

  • CeftazidimCephalosporinGeringfügig

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (Fachinformation zu Ceftazidim, Warnhinweise)

  • CeftriaxonCephalosporinGeringfügig

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (Fachinformation zu Ceftriaxon, Warnhinweise und Vorsichtsmaßnahmen)

  • ChininMalariamittelGeringfügig

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

  • ChlorothiazidThiaziddiuretikumGeringfügig

    Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. (Fachinformation zu Chlorothiazid, Arzneimittelwechselwirkungen)

  • ClofarabinAntimetabolitGeringfügig

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (Fachinformation zu Clofarabin, Warnhinweise und Vorsichtsmaßnahmen)

  • Clomifenselektiver Estrogenrezeptormodulator (SERM)Geringfügig

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (Fachinformation zu Clomifen, Warnhinweise)

  • ClotrimazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • CorticotropinGeringfügig

    The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (Fachinformation zu Corticotropin, Warnhinweise und Vorsichtsmaßnahmen)

  • Dapagliflozin und MetforminSGLT-2-HemmerGeringfügig

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Dapagliflozin und Metformin, Arzneimittelwechselwirkungen)

  • DasatinibGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamfetaminZNS-StimulansGeringfügig

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Dexamfetamin, Arzneimittelwechselwirkungen)

  • DroperidolDopaminantagonistGeringfügig

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (Fachinformation zu Droperidol, Arzneimittelwechselwirkungen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumGeringfügig

    Steroid hormones may be poorly metabolized in patients with impaired liver function. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

  • EconazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Efavirenzantiretrovirales ArzneimittelGeringfügig

    Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (Fachinformation zu Efavirenz, Warnhinweise und Vorsichtsmaßnahmen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelGeringfügig

    Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

  • Empagliflozin und MetforminSGLT-2-HemmerGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Empagliflozin und Metformin, Arzneimittelwechselwirkungen)

  • Enalapril und HydrochlorothiazidACE-HemmerGeringfügig

    Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. (Fachinformation zu Enalapril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • EtacrynsäureSchleifendiuretikumGeringfügig

    Care should also be exercised in patients receiving potassium-depleting steroids. (Fachinformation zu Etacrynsäure, Warnhinweise)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Etonogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

  • EverolimusImmunsuppressivumGeringfügig

    Corticosteroids may be indicated until clinical symptoms resolve. (Fachinformation zu Everolimus, Warnhinweise und Vorsichtsmaßnahmen)

  • FluconazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • FludarabinAntimetabolitGeringfügig

    Steroids may or may not be effective in controlling these hemolytic episodes. (Fachinformation zu Fludarabin, Warnhinweise und Vorsichtsmaßnahmen)

  • FluoxetinSSRIGeringfügig

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (Fachinformation zu Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • GlibenclamidSulfonylharnstoffGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

  • Glibenclamid und MetforminSulfonylharnstoffGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

  • Glipizid und MetforminSulfonylharnstoffGeringfügig

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

  • GlucagonGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • GuselkumabImmunsuppressivumGeringfügig

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (Fachinformation zu Guselkumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Humaninsulin (Normalinsulin)InsulinGeringfügig

    Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Fachinformation zu Humaninsulin (Normalinsulin), Arzneimittelwechselwirkungen)

  • IpratropiumbromidAnticholinergikumGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Ipratropiumbromid und SalbutamolAnticholinergikumGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • IsoprenalinBeta-Adrenozeptor-AgonistGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • ItraconazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • LenalidomidGeringfügig

    Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

  • Linagliptin und MetforminDPP-4-HemmerGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

  • MelphalanGeringfügig

    The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (Fachinformation zu Melphalan, Warnhinweise)

  • MetamfetaminZNS-StimulansGeringfügig

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

  • MetforminBiguanidGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

  • MethohexitalBarbituratGeringfügig

    Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (Fachinformation zu Methohexital, Warnhinweise)

  • MiconazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • MidodrinAlpha-Adrenozeptor-AgonistGeringfügig

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (Fachinformation zu Midodrin, Arzneimittelwechselwirkungen)

  • MirabegronBeta-Adrenozeptor-AgonistGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • MitoxantronGeringfügig

    Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

  • NaltrexonOpioidantagonistGeringfügig

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Fachinformation zu Naltrexon, Warnhinweise und Vorsichtsmaßnahmen)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norelgestromin und Ethinylestradiol, Arzneimittelwechselwirkungen)

  • Norethisteron und Ethinylestradiolorales KontrazeptivumGeringfügig

    Steroid hormones may be poorly metabolized in patients with impaired liver function. (Fachinformation zu Norethisteron und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

  • Norgestimat und Ethinylestradiolorales KontrazeptivumGeringfügig

    Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norgestimat und Ethinylestradiol, Arzneimittelwechselwirkungen)

  • Norgestrel und Ethinylestradiolorales KontrazeptivumGeringfügig

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (Fachinformation zu Norgestrel und Ethinylestradiol, Vorsichtsmaßnahmen)

  • Olanzapin und FluoxetinAntipsychotikumGeringfügig

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (Fachinformation zu Olanzapin und Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (Fachinformation zu Olmesartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (Fachinformation zu Olmesartan, Amlodipin und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • OxacillinPenicillin-AntibiotikumGeringfügig

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (Fachinformation zu Oxacillin, Warnhinweise)

  • Phenoxymethylpenicillin (Penicillin V)Penicillin-AntibiotikumGeringfügig

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (Fachinformation zu Phenoxymethylpenicillin (Penicillin V), Warnhinweise)

  • Pioglitazon und MetforminThiazolidindion (Glitazon)Geringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

  • PosaconazolAzol-AntimykotikumGeringfügig

    If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR REDIHALER therapy, but at times therapy with QVAR REDIHALER may need to be temporarily interrupted under close medical supervision. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • PropylthiouracilThyreostatikumGeringfügig

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Propylthiouracil, Warnhinweise)

  • Raloxifenselektiver Estrogenrezeptormodulator (SERM)Geringfügig

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Raloxifen, Arzneimittelwechselwirkungen)

  • RepaglinidGlinidGeringfügig

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

  • RituximabImmunsuppressivumGeringfügig

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Fachinformation zu Rituximab, Warnhinweise und Vorsichtsmaßnahmen)

  • Saxagliptin und MetforminDPP-4-HemmerGeringfügig

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

  • Sitagliptin und MetforminDPP-4-HemmerGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistGeringfügig

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • TenecteplaseGeringfügig

    If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (Fachinformation zu Tenecteplase, Warnhinweise und Vorsichtsmaßnahmen)

  • ThiamazolThyreostatikumGeringfügig

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Thiamazol, Warnhinweise)

  • TobramycinAminoglykosidGeringfügig

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Fachinformation zu Tobramycin, Arzneimittelwechselwirkungen)

  • UmeclidiniumbromidAnticholinergikumGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • UstekinumabImmunsuppressivumGeringfügig

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (Fachinformation zu Ustekinumab, Warnhinweise und Vorsichtsmaßnahmen)

  • VibegronBeta-Adrenozeptor-AgonistGeringfügig

    Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER. (Fachinformation zu Beclometason, Warnhinweise und Vorsichtsmaßnahmen)

  • Vitamin DVitamine und MineralstoffeGeringfügig

    Kortikosteroide wie Prednison verringern die Calciumaufnahme und beeinträchtigen den Vitamin-D-Stoffwechsel, was zum Knochenschwund beiträgt. (NIH Office of Dietary Supplements, Vitamin D)

  • ZiprasidonAntipsychotikumGeringfügig

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Beclometason gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.